Introduction {#S0001}
============

Pancreatic ductal adenocarcinoma (PDAC) accounts for 90 percent of pancreatic cancer, with a 5-year survival rate under 5 percent.[@CIT0001] It is primarily caused by the biological characteristics of early recurrence and metastasis and the lack of early diagnosis methods.[@CIT0002],[@CIT0003] MicroRNAs (miRNAs), a sort of noncoding RNA, have approximately 22 ribonucleotide RNA sequences.[@CIT0003] MiRNAs are very stable in tissue, plasma, feces, and other liquids, and can be quantitatively analyzed using a very small sample size for clinical detection.[@CIT0004] Regarded as either oncogenes or anti-oncogenes, miRNAs help regulate posttranscriptional gene expression.[@CIT0005] Several works have indicated that miRNAs can be identified as biomarkers to diagnose and evaluate the prognosis of PDAC.[@CIT0006],[@CIT0007] For instance, PDAC patients with miR-1-positive tumors had a longer survival time, and miR-1 status was associated with tumor size and TMN stage[@CIT0008]

MiR-193a-3p was first reported by Lagos-Quintana et al, who found that it was a tumor inhibitor and transforming factor of parietal cells in 2003.[@CIT0009] It has now been discovered to play a vital role in multiple diseases. In acute myeloid leukemia, miRNA-193a-3p acts as a tumor suppressor to repress the expression of *KRAS*.[@CIT0010] Other studies show that miR-193a-3p participates in inhibiting tumor progression in lung cancer[@CIT0011] and colorectal cancer.[@CIT0012]

Here, we researched the effect of miR-193a-3p on the proliferation and invasion of PDAC cells and looked into the correlation between miR-193a-3p and the target gene *CCND1* using prediction software as well as experimental verification. We found that miR-193a-3p could act as a tumor inhibitor in PDAC by directly targeting *CCND1*.

Material and methods {#S0002}
====================

Tissue samples {#S0002-S2001}
--------------

We collected 37 samples of formalin-fixed paraffin-embedded (FFPE) PDAC tissue and 42 samples of non-cancerous pancreas tissue from the pathology department of the First Affiliated Hospital of Guangxi Medical University. These samples were confirmed by pathology to come from patients between January 2012 and June 2017 who were treated with neither radiation nor chemotherapy before resection. Written informed consents were obtained from the patients before surgery. This study was approved by the Ethics Committee of the First Hospital of Guangxi Medical University, and conducted in accordance with the Declaration of Helsinki.

Cell culture {#S0002-S2002}
------------

BxPC-3, PANC-1, and Hpde6-C7 cell lines were all accessed from the Cell Bank, Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). These cells were artificially nurtured in a proportionally prepared medium including Dulbecco's modified Eagle's medium, RPMI-1640 medium, fetal bovine serum, and penicillin/streptomycin (Gibco, Grand Island, NY, USA). Culture bottles were put in a humidified incubator with 5% CO2.

qRT‑PCR {#S0002-S2003}
-------

For tissues and cells, all the RNA was extracted according to the instructions of the E.Z.N.A.^®^ FFPE RNA Kit (Omega Bio-Tek, Inc., Norcross, GA, USA) and Total RNA Kit I (Omega). Subsequently, the complementary DNAs (cDNAs) were inversely transcribed in line with the Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany) or the miRNA First Strand cDNA Synthesis (Tailing Reaction) (Sangon Biotech, Shanghai, China). The expression levels of miRNA relative to U6 and those of mRNA relative to were accessed via qRT‑PCR, which was conducted by employing the FastStart Universal SYBR-Green Master (Roche) or the MicroRNAs qPCR Kit (SYBR Green Method) (Sangon Biotech) on an ABI Prism 7500 (Applied Biosystems, Foster City, CA, USA).

Transfection of lentivirus {#S0002-S2004}
--------------------------

The overexpression of miR-193a-3p was conducted via transfecting lentivirus. The PDAC cell suspension was seeded into 6-well plates (2 ml/wall) and then transfected by lentivirus for 16 h, followed by changing the transfection medium into a routine medium. The group with the overexpression of miR-193a-3p was the OE group.

CCK-8 assay {#S0002-S2005}
-----------

Transfected cells were planted in 96-well plates (2000 cells/well) for 24, 48, 72, 96, or 120 h. The CCK-8 reagents were added to each well three hours before the end of culture. A microplate reader was employed to determine the absorbance at 450 nm.

PI-FACS analysis {#S0002-S2006}
----------------

Transfected cells were washed and collected with precooled D-Hanks (pH=7.2\~7.4). After centrifugation, precooled 75% ethanol was used to fix the cells for 1 h. According to the cell quantity, a PI solution was added to re-suspend the cells, so that the cell passing rate ranged from 300\~800 cells/s when the cells were on the flow cytometer. Lastly, the cell cycle distribution was observed.

Apoptosis analysis {#S0002-S2007}
------------------

Using the method of Annexin V-APC Single Staining, we used 4 °C pre-cooled D-Hanks, PBS(phosphate buffered saline), and a 1×binding buffer to wash the cell pellet once (1500 rpm, 5 min centrifuged); then the 1×staining buffer was used to re-suspend the cell precipitation and Annexin V-APC was added to stain it for 10--15 min, keeping it in a dark place at room temperature before conducting flow cytometry.

Dual-luciferase reporter assays {#S0002-S2008}
-------------------------------

Luciferase activity was identified using the Dual-Luciferase^®^ Reporter Assay System (Promega, Madison, WI, USA). HEK293T cells were transfected with the target gene 3' UTR plasmids (*CCND1* 3' UTR+miR-193a-3p) or no-load plasmids (*CCND1* 3' UTR-NC+miR-193a-3p). To make the experimental results more reliable, both the positive reference miRNA group (has-miR-146b vector plasmid) and the positive reference miRNA NC(negative control) group (TRAF6 3′UTR plasmids) were set up.

Bioinformatics analysis {#S0002-S2009}
-----------------------

The miR-193a-3p target genes were predicted using the target gene prediction software miRwalk (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>), which contains 12 online databases. We picked out genes that were predicted by more than seven platforms to conduct the protein-protein interaction analysis via the String database following the procedure that inputting target genes into input boxes of "Multiple proteins" and selecting "Homo sapiens" button. The GO(gene ontology) and KEGG(Kyoto Encyclopedia of Genes and Genomes) analysis were performed through the DAVID tools (<https://david.ncifcrf.gov/>).

Datasets related to miR-193a-3p and *CCND1* expression were searched for in the databases of GEO (Gene Expression Omnibus) using the search strategy. We searched using the following search strategy: "(pancreas OR pancreatic) and (tumor OR cancer OR carcinoma OR adenocarcinoma OR malignan\* OR neoplas\* OR PDAC OR PC OR PAAD)". The expression of miR-193a-3p was also obtained from online database (<http://driverdb.tms.cmu.edu.tw/ym500v3/>).

Results {#S0003}
=======

miR-193a-3p expression in PDAC {#S0003-S2001}
------------------------------

We found the expression of miR-193a-3p was down-regulation in PDAC by analyzing data from online database ([Figure 1A](#F0001){ref-type="fig"}). The result of qRT-PCR suggested that miR-193a-3p expression was decreased in the PDAC cell lines ([Figure 1B](#F0001){ref-type="fig"}). In addition, the expression levels were verified in the 37 cases of PDAC comparing with the 42 cases of adjacent pancreatic tissues. Likewise, miR-193a-3p expression in PDAC tissue was significantly lower than that in tumor adjacent tissue ([Figure 1C](#F0001){ref-type="fig"}). Moreover, combing with database mining, there was a low expression of miR-193a-3p in PDAC patients ([Figure 1D](#F0001){ref-type="fig"}).Figure 1MiR-193a-3p expression in PDAC. (**A**) MiR-193a-3p expression was down-regulated in PDAC tissue in the online databases. (**B**) MiR-193a-3p expression in PANC-1 and BxPC-3 cells was lower than that in Hpde6-C7 cells. (**C**) MiR-193a-3p expression in PDAC tissues was lower than in para-carcinoma tissues. (**D**) Forest plot combining the GEO datasets with our qRT-PCR data showed down-regulated expression of miR-193a-3p in PDAC tissue.**Abbreviations:** PDAC, pancreatic ductal adenocarcinoma; GEO, Gene Expression Omnibus.

Effect of miR-193a-3p overexpression on PDAC cells {#S0003-S2002}
--------------------------------------------------

The results of the CCK-8 assay indicated that cell proliferation could be repressed by increasing miR-193a-3p expression in PDAC cell lines ([Figure 2](#F0002){ref-type="fig"}). Compared to the NC group, the proliferation capacity of BxPC-3 cells was significantly decreased 3 d(*P*=0.001), 4 d(*P*=0.022), and 5 d(*P*=0.002) after transfection, while the multiplication ability of Panc-1 cells was significantly reduced 2 d(*P*=0.006), 3 d(*P*=0.001), 4 d(*P*=0.011), and 5 d(*P*=0.000) after transfection. Afterwards, we carried out a flow cytometry analysis to investigate whether miR-193a-3p impacts PDAC cell proliferation by altering the cell cycle distribution. Compared with the control group, transfected PDAC cells were both visibly blocked in the G2/M phase, while cells in the S phase were reduced. BxPC-3 cells that were overexpressed with miR-193a-3p also had cell cycle arrest in the G1 phase ([Figure 3](#F0003){ref-type="fig"}). According to the results of the Annexin V-APC Single Staining, the overexpression of miR-193-3p significantly induced BxPC-3 and Panc-1 cell apoptosis ([Figure 4](#F0004){ref-type="fig"}).Figure 2Effect of miR-193a-3p overexpression on PDAC cell proliferation. (**A**) The proliferation capacity of BxPC-3 cells was significantly decreased 3 d(*P*=0.001), 4 d(*P*=0.022), and 5 d(*P*=0.002) after transfection. (**B**) The multiplication ability of Panc-1 cells was significantly reduced 2 d(*P*=0.006), 3 d(*P*=0.001), 4 d(*P*=0.011), and 5 d(*P*=0.000) after transfection. (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001).**Abbreviations:**NC, negative control; OE, the overexpression of miR-193a-3p.Figure 3The cycle distribution of PDAC cells after overexpression of miR-193a-3p. (**A** and **B**) Cycle distribution of the BxPC-3 cell line and Panc-1 cell line. (**C**) Statistical analysis of the cell cycle distribution of PDAC.**Abbreviations:**NC, negative control; OE, the overexpression of miR-193a-3p.Figure 4Effect of miR-193a-3p overexpression on the apoptosis of PDAC cells. (**A**) The result of detecting apoptosis after the overexpression of miR-193a-3p. (**B**) Apoptosis rates of the two cell lines in the experimental groups were compared with those in the negative control groups.**Abbreviations:**NC, negative control; OE, the overexpression of miR-193a-3p.

Target gene analysis of miR-193a-3p {#S0003-S2003}
-----------------------------------

The 285 genes that are repeatedly detected by at least eight platforms were selected for later works. The GO analysis showed that these genes were concentrated in 71 pathways, 9 of which were significant (*P*≤0.01; [Figure 5](#F0005){ref-type="fig"}, [Table 1](#T0001){ref-type="table"}). The KEGG analysis of these 285 genes resulted in 37 signaling pathways, of which 14 were significant (*P*≤0.01; [Figure 5](#F0005){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). Interestingly, the gene *CNND1* functioned in many tumor-related pathways, such as Pathways in cancer and MicroRNAs in cancer. What is more, the results of the protein-protein interaction network analysis showed that *CCND1* had a high interaction with all the pivotal genes ([Figure 6](#F0006){ref-type="fig"}).Table 1GO analysis of miR-193a-3p target genesTermTypeCount*P*-valueFDRProteasome-mediated ubiquitin-dependent protein catabolic processBiological process96.71E-041.058Cell migrationBiological process80.0034.356Negative regulation of cell proliferationBiological process110.0045.490Regulation of axon extension involved in axon guidanceBiological process30.0046.427Regulation of synaptic transmission, GABAergicBiological process30.00811.436Retrograde transport, endosome to GolgiBiological process50.01014.316Branchiomotor neuron axon guidanceBiological process30.01014.320Semaphorin receptor complexCellular component30.00910.941Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingMolecular function100.0078.270 Table 2KEGG pathway analysis of miR-193a-3p target genesTermGenes*P*-valueFDRMicroRNAs in cancer*PRKCA, IRS2, BMPR2, IGF2BP1, BCL2L2, MMP16, PTEN, TGFB2, CCND1, KRAS, CRKL, SOS2, PDGFRA, PLAU*9.95E-080.000FoxO signaling pathway*USP7, IGF1R, CCND1, IRS2, KRAS, SOS2, MAPK8, FOXO4, PTEN, TGFB2*1.23E-040.152Pathways in cancer*TRAF1, PRKCA, RUNX1T1, ARHGEF12, PTEN, TGFB2, IGF1R, CCND1, KRAS, CRKL, ADCY9, GNB1, SOS2, PDGFRA, LAMC2, MAPK8, LAMC1*1.74E-040.216Glioma*PRKCA, IGF1R, CCND1, KRAS, SOS2, PDGFRA, PTEN*3.62E-040.447GnRH signaling pathway*KRAS, ADCY9, MAP3K3, MAP3K1, SOS2, MAPK8, MMP14*0.00131.642Focal adhesion*PRKCA, IGF1R, CCND1, CRKL, SOS2, PDGFRA, MAPK8, LAMC2, LAMC1, PTEN*0.00334.042Hepatitis B*PRKCA, CCND1, YWHAZ, KRAS, MAP3K1, MAPK8, PTEN, TGFB2*0.00485.807Transcriptional misregulation in cancer*TRAF1, IGF1R, KMT2A, RUNX1T1, ETV1, SIX4, PLAU, MYCN*0.00779.151Proteoglycans in cancer*PRKCA, IGF1R, CCND1, KRAS, SOS2, RPS6KB2, ARHGEF12, PLAU, TGFB2*0.00799.323ErbB signaling pathway*PRKCA, CRKL, KRAS, SOS2, RPS6KB2, MAPK8*0.00910.570Prostate cancer*IGF1R, CCND1, KRAS, SOS2, PDGFRA, PTEN*0.00910.570AMPK signaling pathway*IGF1R, CCND1, IRS2, PPP2R5C, ACACA, RPS6KB2, CAB39*0.00910.633Acute myeloid leukemia*CCND1, KRAS, SOS2, RUNX1T1, RPS6KB2*0.00910.703Axon guidance*PLXNA4, KRAS, SEMA4G, PLXNA1, UNC5B, PLXNA2, ARHGEF12*0.009811.428 Figure 5Bubble Chart of the results of the GO and KEGG analysis. Pathway visualization of the results of the GO and KEGG analysis of the miR-193a-3p target genes, which was performed in ImageGP (<https://www.ehbio.com/ImageGP/>).**Abbreviations:**BP, biological process; CC, cellular component; MF, molecular function; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.Figure 6Protein-protein interaction network of miR-193a-3p target genes.

CCND1 expression in PDAC {#S0003-S2004}
------------------------

Our qRT-PCR data illustrated that *CCND1* expression in FFPE PDAC tissues (3.2482±4.3472) was significantly higher than in non-tumor tissues (1.5356±1.64881; [Figure 7A](#F0007){ref-type="fig"}). Meanwhile, we mined 11 databases to detect *CCND1* expression in PDAC and para-carcinoma pancreatic tissues by searching GEO. Subsequently, a forest plot of *CCND1* expression was performed by combining our data with the published findings. The results illustrated that *CCND1* expression in PDAC tissues was significantly higher than that of normal pancreatic tissues (SMD=0.69, CI=0.38--0.99, *P*\<0.001; [Figure 7B](#F0007){ref-type="fig"}).Figure 7The expression of *CCND1* in PDAC. (**A**) *CCND1* expression in FFPE PDAC tissues and para-carcinoma tissues. (**B**) Forest plot for the miR-193a-3p expression in PDAC.**Abbreviation:** FFPE, formalin-fixed paraffin-embedded.

Correlation between miR-193a-3p and CCND1 {#S0003-S2005}
-----------------------------------------

Through searching online prediction software, we found that there were complementary bases between miR-193a-3p and *CCND1* ([Figure 8A](#F0008){ref-type="fig"}). The results of the dual-luciferase reporter assay showed that there was direct binding sites between miR-193a-3p and *CCND1* ([Figure 8B](#F0008){ref-type="fig"}). The expression of miR-193a-3p and *CCND1* were detected in the same samples. After matching the samples, a correlation analysis was performed. The result showed the correlation was not statistically significant (r=−0.0021, *P*=0.99; [Figure 8C](#F0008){ref-type="fig"}). More notably, *CCND1* expression was significantly decreased in PDAC cells with miR-193a-3p overexpression ([Figure 8D](#F0008){ref-type="fig"}).Figure 8The relationship between miR-193a-3p and *CCND1*. (**A**) Base-complementing sequences of miR-193a-3p and *CCND1*. (**B**) Relative luciferase activity in cells with *CCND1* 3ʹUTR+miR-193a-3p was reduced compared to cells with *CCND1* 3ʹUTR-NC+miR-193a-3p. The relative luciferase activity in the group of positive reference miRNA was lower than in the group of positive reference miRNA NC. (**C**) Negative correlation between miR-193a-3p and *CCND1* in FFPE PDAC tissue. (**D**) Reduced expression of *CCND1* in the two cell lines after the overexpression of miR-193a-3p.**Abbreviations:**NC, negative control; OE, the overexpression of miR-193a-3p; FFPE, formalin-fixed paraffin-embedded.

Discussion {#S0004}
==========

The occurrence and development of PDAC is a complex, multistep process involving multiple genes and epigenetic changes.[@CIT0013] It is needed to investigate the molecular basis of the occurrence and development of PDAC in order to seek more effective diagnostic and therapeutic methods. Over the past decades, numerous studies have demonstrated the important role of miRNAs in the progression of multiple tumors. MiRNAs control various tumor-related courses, including propagation, mobility and invasion, apoptosis, angiogenesis, and even the transdifferentiation of stem cells.[@CIT0014],[@CIT0015] MiRNA is considered to be not only a biomarker and prognostic factor, but also a potential treatment for certain cancers.[@CIT0016]

MiR-193a-3p, a member of the miR-193 family, is located at 17q11.2. Recently, it was reported that miR-193a-3p expression was decreased in tumors such as colorectal cancer,[@CIT0017] lung cancer,[@CIT0010] and liver cancer.[@CIT0018] Likewise, we found that miR-193a-3p expression in 37 cases of PDAC tissues was significant lower than in the 42 cases of non-tumor tissues. The low level of miR-193a-3p expression was examined in PANC-1 and BxPC-3. It also turned out to be down-regulated in PDAC after we performed a meta-analysis combining the qRT-PCR experiment with data from GEO. The down-regulated expression of miR-193a-3p corresponded to a poor prognosis.[@CIT0012]

Recent studies have uncovered that miR-193a-3p was involved in several biological processes such as proliferation, apoptosis, and migration.[@CIT0019],[@CIT0020] We researched the biological functions of PANC-1 and BxPC-3 to investigate how miR-193a influences the biological behavior of PDAC cells. In this work, after overexpressing miR-193a-3p in PDAC cells, we found the cell-cycle was blocked in the G1 and G2/M phases. Although the apoptosis analysis showed that the cell apoptosis rate was low (\<5%), the overexpression miR-193a-3p had a tendency to promote pancreatic cancer cell apoptosis and the difference was statistically significant. The results were consistent with the results that the cell proliferation was significantly inhibited after the overexpression of miR-193a-3p in the CCK-8 assay. Existing research has demonstrated that miRNAs could influence the occurrence of colorectal cancer through cell cycle control.[@CIT0021],[@CIT0022] Colon cancer cells were blocked during the transition from S phase to G2/M phase; however, cells were detained in the G2/M phase when miR-193a was overexpressed in the cells, thereby promoting the apoptosis of the colon cells.[@CIT0023] The transition from the G1 and S phases was synergistically inhibited by miR-193a-3p and other miRNAs in breast cancer.[@CIT0024] In addition, miR-193a-3p inhibited breast cancer cell proliferation and apoptosis by inhibiting the expression of *PTP1B*.[@CIT0025] Thus, miR-193a-3p expression was lower in PDAC and an overexpression of miR-193a-3p could repress cell proliferation and motivate the apoptosis of PDAC cells, which indicates that miR-193a-3p may be a potential tumor inhibitor for PDAC.

At present, there are a number of studies that indicated miR-193a-3p influences tumor progression by targeting genes. MiR-193a-3p down-regulation could inhibit cell proliferation, migration, and chemical resistance by targeting *PTEN*(phosphatase and tensin homolog)in stomach cancer[@CIT0026] and could inhibit cell multiplication and migration in renal cell cancer.[@CIT0027] LINC00152 has been shown to enhance gastric cancer cell proliferation by down-regulating miR-193a-3p expression and increasing *MCL1* expression.[@CIT0028] MiR-193a-3p took part in regulating the proliferation by targeting *c-kit* in AML cells[@CIT0029] and by affecting the expression of *ERBB4* in lung cancer cells.[@CIT0030] MiR-193a-3p also inhibited cell proliferation metastasis in renal cancer by targeting *PTEN*[@CIT0027] and induced apoptosis by targeting *ST3GalIV*.[@CIT0031]

In this study, we applied target gene prediction tools to explore whether miR-193a-3p suppresses PDAC cell proliferation by targeting genes. As a result, *CCND1* was found to be key gene in the network analysis and was concentrated in a variety of tumor pathways. The *CCND1* gene, located on chromosome 11q13, was overexpressed in multiple human cancers of the breast,[@CIT0032] stomach,[@CIT0033] and ovarian cancer[@CIT0034] as a well-known oncogene. In pancreatic cancer, *CCND1* expression was high and significantly associated with the degree of differentiation and a poor prognosis.[@CIT0035] A functional analysis showed that a *CCND1* knockdown could inhibit cell proliferation, soft AGAR cloning, metastasis, metabolism, and cell growth.[@CIT0036],[@CIT0037] The reduced expression of *CCND1* enhanced the chemotherapy sensitivity of patients to 5-fluorouracil, 5-fluoro-2'-deoxyuridine, and mitoxantrone by down-regulating various chemo-resistant genes in pancreatic cancer.[@CIT0038] Therefore, the regulation of the miR-193a-3p/*CCND1* axis may be a new method of treatment to repress the fast growth and metastasis of pancreatic cancer.

We explored the correlation between *CCND1* and miR-193a-3p and found there were bases' binding sites between them. qRT-PCR detection in pancreatic cancer cells with an overexpression of miR-193a-3p indicated that *CCND1* expression significantly decreased compared with the control group. This result suggested that miR-193a-3p can negatively regulate *CCND1* expression at the mRNA level in PDAC cells. Furthermore, miR-193a-3p overexpression reduced the luciferase activity of *CCND1* 3ʹUTR, which demonstrated that a direct binding site existed between miR-193a-3p and *CCND1*. However, there was no significantly negative correlation in their expression (R=−0.0021). Perhaps the insignificantly statistic difference of negative correlation resulted from the deficient number of cases. In normal physiological functions, *CCND1* acted as a key sensor, mediating cellular functions by binding to cyclin-dependent kinases. *CCND1* could make the function of suppressing the cell cycle of retinoblastoma proteins inactive as well.[@CIT0039] Therefore, miR-193a-3p overexpression led to the PDAC cell cycle's block at the G1 phase, which have been caused by inhibiting *CCND1* expression. Nevertheless, *CCND1* may have other carcinogenic functions besides its influence on the cell cycle. Studies on tumor models revealed that *CCND1* could act as a transcriptional regulatory factor and potentially cause chromosomal instability.[@CIT0040],[@CIT0041] It is worth noting that previously *CCND1* was discovered to promote DNA repair by binding with recombinant activator genes and homologous DNA recombination,[@CIT0042] which was also considered to be the cause of anti-apoptosis of cancer cells. In this study, *CCND1* expression was decreased after miR-193a-3p overexpression in PDAC cells. The presence of a base binding site between miR-193a-3p and *CCND1* was detected by bioinformatics prediction software. Beyond that, the luciferase assay showed that the former inhibited the latter's expression by binding directly to 3ʹUTR at the post-transcriptional level. Therefore, the inhibition of *CCND1* expression in pancreatic cancer may be a promising therapeutic strategy.

Conclusion {#S0005}
==========

Our findings illustrated a potential tumor suppressor function of miR-193a-3p in PDAC progress by targeting *CCND1*, which offers new ideas for exploring the molecular mechanism of PDAC and may provide a possible therapeutic strategy for PDAC treatment. However, the mechanism of their interaction in pancreatic cancer has not been fully elucidated and further studies are needed in deeper experiments.
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